Cargando…
Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
This editorial discusses a novel basal insulin analog, insulin degludec. It describes the limitations of existing basal insulins, and builds the case for a better analog. The editorial discusses the evidence to support the efficacy, safety, tolerability, and flexibility of degludec, and assesses its...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889334/ https://www.ncbi.nlm.nih.gov/pubmed/24254338 http://dx.doi.org/10.1007/s13300-013-0047-6 |
| _version_ | 1782299181392592896 |
|---|---|
| author | Kalra, Sanjay |
| author_facet | Kalra, Sanjay |
| author_sort | Kalra, Sanjay |
| collection | PubMed |
| description | This editorial discusses a novel basal insulin analog, insulin degludec. It describes the limitations of existing basal insulins, and builds the case for a better analog. The editorial discusses the evidence to support the efficacy, safety, tolerability, and flexibility of degludec, and assesses its utility as part of a person-centered approach to diabetes management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-013-0047-6) contains supplementary material, which is available to authorized users. |
| format | Online Article Text |
| id | pubmed-3889334 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-38893342014-01-14 Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin Kalra, Sanjay Diabetes Ther Editorial This editorial discusses a novel basal insulin analog, insulin degludec. It describes the limitations of existing basal insulins, and builds the case for a better analog. The editorial discusses the evidence to support the efficacy, safety, tolerability, and flexibility of degludec, and assesses its utility as part of a person-centered approach to diabetes management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-013-0047-6) contains supplementary material, which is available to authorized users. Springer Healthcare 2013-11-20 2013-12 /pmc/articles/PMC3889334/ /pubmed/24254338 http://dx.doi.org/10.1007/s13300-013-0047-6 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
| spellingShingle | Editorial Kalra, Sanjay Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin |
| title | Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin |
| title_full | Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin |
| title_fullStr | Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin |
| title_full_unstemmed | Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin |
| title_short | Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin |
| title_sort | insulin degludec: a significant advancement in ultralong-acting basal insulin |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889334/ https://www.ncbi.nlm.nih.gov/pubmed/24254338 http://dx.doi.org/10.1007/s13300-013-0047-6 |
| work_keys_str_mv | AT kalrasanjay insulindegludecasignificantadvancementinultralongactingbasalinsulin |